The Challenges of Managing Pediatric Diabetes and Other Endocrine Disorders During the COVID-19 Pandemic: Results From an International Cross-Sectional Electronic Survey.
COVID-19
/ epidemiology
Child
Child, Preschool
Cross-Sectional Studies
Diabetes Mellitus
/ epidemiology
Disease Management
Endocrine System Diseases
/ epidemiology
Equipment and Supplies, Hospital
/ trends
Female
Health Personnel
/ trends
Humans
Internationality
Male
Online Systems
Surveys and Questionnaires
COVID-19
adrenal
children
diabetes
growth
obesity and metabolic syndrome
puberty
thyroid
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
07
2021
accepted:
15
10
2021
entrez:
22
11
2021
pubmed:
23
11
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Frequency, dimensions, management, and outcomes of the COVID-19 pandemic in children with endocrine disorders and diabetes were assessed. A cross-sectional electronic survey was distributed to the global network of endocrine societies. Respondents' professional and practice profiles, clinic sizes, their country of practice, and the impact of COVID-19 on endocrine diseases were investigated. Respondents from 131 pediatric endocrine centers in 51 countries across all continents completed the survey. Routine check-ups and education were altered in most pediatric endocrine clinics. Over 20% of clinics experienced a shortage of critical medications or essential supplies. ICU treatment was required for patients with diabetes and COVID-19 in 21.2% of centers. In diabetes, 44% of respondents reported increased diabetic ketoacidosis episodes in newly diagnosed cases and 30% in established cases. Biopsychosocial and behavioral changes were explicitly reported to be occurring among pediatric patients with endocrine disorders. This large global survey conducted during the COVID-19 pandemic highlights that diabetes is more challenging to manage than any other pediatric endocrine disorder, with an increased risk of morbidity. Psychological distress due to COVID-19 needs to be recognized and addressed. The importance of close contact with healthcare professionals should be emphasized, and medical supplies should be readily available to all patients.
Sections du résumé
Background
Frequency, dimensions, management, and outcomes of the COVID-19 pandemic in children with endocrine disorders and diabetes were assessed.
Methods
A cross-sectional electronic survey was distributed to the global network of endocrine societies. Respondents' professional and practice profiles, clinic sizes, their country of practice, and the impact of COVID-19 on endocrine diseases were investigated.
Results
Respondents from 131 pediatric endocrine centers in 51 countries across all continents completed the survey. Routine check-ups and education were altered in most pediatric endocrine clinics. Over 20% of clinics experienced a shortage of critical medications or essential supplies. ICU treatment was required for patients with diabetes and COVID-19 in 21.2% of centers. In diabetes, 44% of respondents reported increased diabetic ketoacidosis episodes in newly diagnosed cases and 30% in established cases. Biopsychosocial and behavioral changes were explicitly reported to be occurring among pediatric patients with endocrine disorders.
Conclusions
This large global survey conducted during the COVID-19 pandemic highlights that diabetes is more challenging to manage than any other pediatric endocrine disorder, with an increased risk of morbidity. Psychological distress due to COVID-19 needs to be recognized and addressed. The importance of close contact with healthcare professionals should be emphasized, and medical supplies should be readily available to all patients.
Identifiants
pubmed: 34803908
doi: 10.3389/fendo.2021.735554
pmc: PMC8602836
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
735554Informations de copyright
Copyright © 2021 Elbarbary, dos Santos, de Beaufort, Wiltshire, Pulungan and Scaramuzza.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Diabetes Technol Ther. 2020 Jun;22(6):449-453
pubmed: 32383989
Pathogens. 2016 Dec 06;5(4):
pubmed: 27929449
Horm Res Paediatr. 2020;93(6):343-350
pubmed: 33486483
Postgrad Med J. 2020 Jul;96(1137):412-416
pubmed: 32527756
JAMA. 2020 Aug 25;324(8):801-804
pubmed: 32702751
Endocrine. 2020 Jun;68(3):471-474
pubmed: 32507963
Horm Res Paediatr. 2019;92(6):345-346
pubmed: 32272473
BMC Infect Dis. 2021 Jan 20;21(1):87
pubmed: 33472588
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1459-1462
pubmed: 32771918
Front Pediatr. 2020 Dec 04;8:605807
pubmed: 33344389
JAMA Pediatr. 2020 Oct 1;174(10):e202430
pubmed: 32492092
Diabetes Care. 2020 Jul;43(7):e72-e74
pubmed: 32409499
JAMA Pediatr. 2020 Sep 1;174(9):868-873
pubmed: 32392288
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Rev Endocr Metab Disord. 2020 Dec;21(4):495-507
pubmed: 32643004
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Diabet Med. 2021 Jan;38(1):e14417
pubmed: 33020999
Eur J Endocrinol. 2017 Apr;176(4):471-480
pubmed: 28223394
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
MMWR Morb Mortal Wkly Rep. 2020 Jul 24;69(29):945-950
pubmed: 32701937
J Endocr Soc. 2020 Oct 01;4(11):bvaa144
pubmed: 33145472
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
Acta Paediatr. 2020 Jul;109(7):1497-1498
pubmed: 32279351
N Engl J Med. 2020 Aug 20;383(8):789-790
pubmed: 32530585
Science. 2020 May 22;368(6493):860-868
pubmed: 32291278
Diabetes Care. 2020 Nov;43(11):2870-2872
pubmed: 32778554
Eur J Endocrinol. 2020 Jul;183(1):G33-G39
pubmed: 32438340
Diabet Med. 2021 Jan;38(1):e14427
pubmed: 33067861
Horm Metab Res. 2020 Nov;52(11):769-774
pubmed: 32898896
Diabetes Care. 2015 Mar;38(3):453-9
pubmed: 25650362
Orphanet J Rare Dis. 2020 Aug 31;15(1):228
pubmed: 32867855
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Endocrinol Diabetes Metab. 2021 Jun 03;4(3):e00262
pubmed: 34268455
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Int J Clin Pract. 2021 Jan;75(1):
pubmed: 32946641
Diabetes Technol Ther. 2020 Jun;22(6):444-448
pubmed: 32396395
Rev Endocr Metab Disord. 2020 Nov 25;:
pubmed: 33241508
Thyroid. 2016 Oct;26(10):1343-1421
pubmed: 27521067
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Pediatr Diabetes. 2020 Nov;21(7):1083-1092
pubmed: 32686287
Endocrine. 2020 Apr;68(1):2-5
pubmed: 32279224
Nat Commun. 2020 May 8;11(1):2260
pubmed: 32385239
J Pediatr. 2020 Aug;223:186-187
pubmed: 32387113
Eur J Endocrinol. 2020 Aug;183(2):G67-G77
pubmed: 32508313
Diabetes Spectr. 2019 May;32(2):171-175
pubmed: 31168290